ClinicalTrials.gg
CompletedNCT00189943Updated Sep 19, 2005

Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects

A Phase 1 interventional study of MVA-BN in Smallpox, sponsored by Bavarian Nordic. Completed at 1 site in Germany. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2005-09-19.

Sponsored by Bavarian Nordic · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing MVA-BN smallpox vaccine in Smallpox — none open to participants now, none under way, none of them phase 3. MVA-BN smallpox vaccine · Smallpox.

Enrollment
13th of 16
90 · median 196
Started
2001
the only one that year
Phase 1
3 of 16
none open now
Registered
4th of 16
by date
Lead sponsor
8 of 16
Bavarian Nordic

Among the 16 studies testing MVA-BN smallpox vaccine in Smallpox, this one is the 13th largest by enrollment, is the only one that started in 2001, is one of 3 in phase 1, and was the 4th registered.

Smallpox

73 studies on the registry are indexed under Smallpox; 5 are open to participants now.

Browse Smallpox studies →

Open to participants now

None of the 16 studies testing MVA-BN smallpox vaccine in Smallpox is open now. The open studies under Smallpox, anywhere →

About MVA-BN smallpox vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2 Smallpox studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 20 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing MVA-BN smallpox vaccine in Smallpox as a file.
02

Study summary

The purpose of this study is to collect information on the safety, tolerability and immunogenicity of an investigational smallpox vaccine at different doses and using different routes of administration in vaccinia-naive and vaccinated healthy volunteers

03

Conditions studied

  • Smallpox

Browse trials for

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects, aged 20 - 55 years
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Prior vaccination against smallpox (study part I only)
  • Abnormalities suspicious of any underlying disease, detected at routine tests prior to study inclusion.
  • Any immune modifying therapy within 4 weeks prior to entry
  • Participation in any other investigating drug trial
  • Known allergy to a component which may be part of the vaccine
  • Allergic reaction or any other severe adverse effects experienced after previous smallpox vaccination (study Part II only)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
90 participants

Interventions

06

Study locations

1 site
  • PharmPlanNet Contract Research GmbH
    Moenchengladbach, 41061, Germany
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2001 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Apr 2001
Completion
Jul 2003
Last update
Sep 19, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Sep 19, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00189943
Lead sponsor
Bavarian Nordic
First posted
Sep 19, 2005
Start date
Apr 2001
Completion
Jul 2003
Last update
Sep 19, 2005

Study contacts

Karl M Eckl, MD
principal investigator · PharmPlanNet Cantract Research GmbH
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVA-BN smallpox vaccine

Start the discussion